Skip to content
OpenCapital
Get started

Pfizer PFE FSME-IMMUN/TicoVac — Revenues:

Other product segments

Eliquis
$2.17B+12.6%
Prevnar Family
$1.69B+1.8%
Vyndaqel family
$1.6B+7.8%
Ibrance
$1.01B+3.2%
All Other Hospital and Biosimilars
$953M—
All other Primary Care
$654M+7.4%
Padcev
$591M+38.7%
All other Specialty Care
$579M+19.1%
Xtandi
$444M-3.1%
Oncology Biosimilars
$409M+54.9%
Royalty
$396M+28.6%
All other Oncology
$376M-0.3%
Nurtec ODT/Vydura
$353M+42.3%
Lorbrena
$305M+37.4%
Pfizer CentreOne
$289M+5.9%
Comirnaty
$232M-58.9%
Paxlovid
$219M-69.9%
Inlyta
$214M-2.3%
Sulperazon (Outside the U.S. and Canada)
$199M+21.3%
Adcetris
$190M-12.8%
Inflectra
$182M—
Abrysvo
$180M+37.4%
Xeljanz
$180M+40.6%
Braftovi/Mektovi
$174M+27.9%
Zavicefta (Outside the U.S. and Canada)
$150M+11.1%
Enbrel (Outside the U.S. and Canada)
$138M-1.4%
Bosulif
$129M-14.6%
Octagam
$122M—
Tukysa
$122M+19.6%
Zithromax
$112M-29.1%
Orgovyx
$109M—
Genotropin
$93M—
Elrexfio
$80M+33.3%
Cibinqo
$76M+31.0%
Talzenna
$50M+25.0%
Tivdak
$33M0.0%

Similar metrics at other companies

Phibro Animal Health logo
PAHCVaccines — Revenue
$38.63M+15.7%
Novavax logo
NVAXProduct sales — Total Revenue
$42.2M-93.2%
Eli Lilly logo
LLYOther immunology — Revenue
$470M+44.2%
Biogen logo
BIIBTecfidera — Revenue
$2.48B+1.9%
Adaptive Biotechnologies logo
ADPTImmune Medicine Business — Revenue
$3.78M-56.6%
Biogen logo
BIIBTECFIDERA — Total Revenue
$109.5M-46.9%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$138.21B-3.7%
Enterprise value$200.88B-1.3%
P/E11.4×—
P/S2.2×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's fsme-immun/ticovac — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's fsme-immun/ticovac — revenues:?
Pfizer (PFE) reported fsme-immun/ticovac — revenues: of $81M in Q1 2026.
How has Pfizer's fsme-immun/ticovac — revenues: changed year-over-year?
Pfizer's fsme-immun/ticovac — revenues: increased by 28.6% year-over-year, from $63M to $81M.
What is the long-term trend for Pfizer's fsme-immun/ticovac — revenues:?
Over 4 years (2021 to 2025), Pfizer's fsme-immun/ticovac — revenues: has grown at a 14.6% compound annual growth rate (CAGR), from $185M to $319M.
What does fsme-immun/ticovac — revenues: mean?
This metric represents the total gross sales generated from the specific vaccine product line focused on tick-borne encephalitis (TBE) prevention. It captures the market demand and commercial performance of this specialized immunological product within the company's broader vaccine portfolio. Tracking this revenue stream helps investors assess the stability and growth trajectory of niche, high-barrier-to-entry preventative healthcare products.